CMMB - CIK 0001534248
The table below shows Chemomab Therapeutics Ltd.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.56M | $6.07M | $9.29M | $13.52M | $15.19M | $5.39M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $13.43M |
| $16.04M |
| $20.90M |
| $41.74M |
| $62.69M |
| $6.12M |
| Property, plant & equipment | $176.00K | $250.00K | $303.00K | $367.00K | $357.00K | $12.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $13.81M | $16.96M | $22.15M | $43.06M | $64.35M | $6.18M |
| Accounts payable | - | - | - | - | - | - |
| Total current liabilities | $1.48M | $3.22M | $4.84M | $6.75M | $2.65M | $2.59M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $1.48M | $3.43M | $5.15M | $6.84M | $2.89M | $2.60M |
| Retained earnings | -$111.62M | -$102.62M | -$88.68M | -$63.82M | -$36.17M | -$117.04M |
| Total equity | $12.33M | $13.54M | $17.00M | $36.22M | $61.47M | $3.58M |